PMID- 12517270
OWN - NLM
STAT- MEDLINE
DCOM- 20031219
LR  - 20191025
IS  - 1471-2598 (Print)
IS  - 1471-2598 (Linking)
VI  - 2
IP  - 8
DP  - 2002 Dec
TI  - Dendritic cell-based vaccines and therapies for cancer.
PG  - 919-28
AB  - Dendritic cells (DCs) are the most potent professional antigen-presenting cells 
      (APCs), and are capable of stimulating naive T cells and driving primary immune 
      responses. Due to this unique property, DCs represent both vectors and targets 
      for immunological intervention in numerous diseases and are optimal candidates 
      for vaccination protocols in cancer. This review provides an overview of DC 
      immunobiology and the integration of these important APCs in immunotherapies for 
      cancer.
FAU - Tatsumi, Tomohide
AU  - Tatsumi T
AD  - L1.32e Hillman Cancer Centre-UPCI Research Pavillion, L5117 Center Avenue, 
      Pittsburgh, PA 15213, USA.
FAU - Storkus, Walter J
AU  - Storkus WJ
LA  - eng
GR  - CA 63350/CA/NCI NIH HHS/United States
GR  - CA 73743/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Autoimmunity/immunology
MH  - Cancer Vaccines/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*immunology/physiology
MH  - Humans
MH  - Immunization Schedule
MH  - Immunotherapy/*methods
MH  - Neoplasms/*immunology/*therapy
MH  - T-Lymphocytes/immunology
RF  - 123
EDAT- 2003/01/09 04:00
MHDA- 2003/12/20 05:00
CRDT- 2003/01/09 04:00
PHST- 2003/01/09 04:00 [pubmed]
PHST- 2003/12/20 05:00 [medline]
PHST- 2003/01/09 04:00 [entrez]
AID - 10.1517/14712598.2.8.919 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2002 Dec;2(8):919-28. doi: 10.1517/14712598.2.8.919.